Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 1998

View Archived Issues

Calypte Biomedical to acquire assets of Cambridge Biotech

AMBI seeks partners to develop injectable nisin for treatment of hospital-acquired infections

Abgenix initiates a phase I/II clinical trial in patients with psoriasis

Bausch & Lomb to manufacture Lidakol for treatment of oral-facial herpes

Ascent to promote Warner-Lambert's Omnicef

AxyS initiates phase I studies of APC-2059 for treatment of acute inflammatory bowel disease

IntraBiotics receives milestone payment from Pharmacia & Upjohn

Adozelesin displays marginal efficacy in previously untreated metastatic breast cancer

Significant protection against ischemic injury in cortex of rats primed with estradiol

U.S. patent covers transgenically produced rhATIII

First clinical trial of human gene therapy for hemophilia begins

Genzyme General receives FDA approval for Thyrogen

Dyax and Genzyme General to develop new antiinflammatory treatment

Final marketing application filed for Ampligen in E.U.

rNAPc2 enters phase II trials in U.S. and Europe

Sanofi, Synthelabo plan another significant European drug company merger

Cytogen submits NDS for ProstaScint for approval in Canada and highlights new clinical data

MedImmune and Pasteur Merieux Connaught develop second-generation Lyme disease vaccine

Harris FRC establishes safety of candidate antiepileptic drug in volunteer studies

Second-generation PD diagnostic enters preclinical development at BLSI

Accutin, an RGD-containing peptide with angiogenesis-inhibitory activity

Health Canada approves first new incontinence medication in over a decade

Agents for ulcers synthesized and evaluated at Shiseido

American Home Products describes preferential COX-2 inhibitors

New HIV protease inhibitors in development at Monsanto

Pharmacokinetic studies support chronic dosing of FK-143

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...